z-logo
Premium
The Immunohistochemical Localization of New Membrane‐Associated Placental Tissue Proteins (MP 2 A, B, C, D, and E) in Human and Cynomolgus Monkey Placentae
Author(s) -
Hirai Yasuo,
Inaba Noriyuki,
Sato Naomi,
Fukazawa Kazuo,
Yamauchi Kazuhiro,
Takamizawa Hiroyoshi,
Hasumi Katsuhiko,
Masubuchi Kazumasa,
Bohn Hans
Publication year - 1992
Publication title -
asia‐oceania journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 0389-2328
DOI - 10.1111/j.1447-0756.1992.tb00316.x
Subject(s) - syncytiotrophoblasts , immunoperoxidase , decidua , biology , stroma , placenta , immunohistochemistry , fetal membrane , staining , pathology , microbiology and biotechnology , antibody , immunology , fetus , monoclonal antibody , pregnancy , medicine , genetics
New membrane‐associated placental tissue proteins (MP 2 A, B, C, D, and E) were investigated by avidin‐biotin immunoperoxidase technique in the human and cynomolgus monkey placentae, decidua and umbilical cords. In human early placentae, MP 2 A, B, C, and E were localized mainly in the membrane of villous syncytiotro‐phoblasts and cytotrophoblasts. Histiocytes in the villous stroma were positive for MP 2 A, B, D, and E. In human term placentae, obvious positive staining for MP 2 A, B, C, and E was observed in the membrane of villous syncytiotrophoblasts, in the amniotic epithelium, and in the umbilical cord sheath. Histiocytes in the villous stroma were positive for MP 2 A, B, C, E, and especially for MP 2 D. Importantly, MP 2 A, C, and E were positive in polymorphonuclear neutrophils, since most of these common antigens are also carcinoma‐associated, suggesting clinical usage of MP 2 proteins as a new tumor marker. In the cynomolgus monkey placentae, similar immuno‐staining results were obtained. The monkey can thus serve as a experimental model for the investigation of the placental proteins.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here